144 related articles for article (PubMed ID: 34365462)
41. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
43. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
44. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
45. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
47. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.
Mittendorf EA; Chavez-MacGregor M; Vila J; Yi M; Lichtensztajn DY; Clarke CA; Giordano SH; Hunt KK
Ann Surg Oncol; 2017 Nov; 24(12):3502-3509. PubMed ID: 28726077
[TBL] [Abstract][Full Text] [Related]
48. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
49. Validation of the AJCC 8th prognostic system for breast cancer in an Asian healthcare setting.
Wong RX; Wong FY; Lim J; Lian WX; Yap YS
Breast; 2018 Aug; 40():38-44. PubMed ID: 29677569
[TBL] [Abstract][Full Text] [Related]
50. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
Cao L; Sun PL; Yao M; Jia M; Gao H
Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
[TBL] [Abstract][Full Text] [Related]
51. Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.
Aldrees R; Gao X; Zhang K; Siegal GP; Wei S
Mod Pathol; 2021 Feb; 34(2):291-299. PubMed ID: 32778677
[TBL] [Abstract][Full Text] [Related]
52. Comparison of AJCC Anatomic and Clinical Prognostic Stage Groups in Breast Cancer: Analysis of 3322 Cases From a Single Institution.
Kurundkar A; Gao X; Zhang K; Britt JP; Siegal GP; Wei S
Clin Breast Cancer; 2018 Dec; 18(6):e1347-e1352. PubMed ID: 30078612
[TBL] [Abstract][Full Text] [Related]
53. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.
Braun L; Mietzsch F; Seibold P; Schneeweiss A; Schirmacher P; Chang-Claude J; Peter Sinn H; Aulmann S
Mod Pathol; 2013 Sep; 26(9):1161-71. PubMed ID: 23558572
[TBL] [Abstract][Full Text] [Related]
54. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
[TBL] [Abstract][Full Text] [Related]
56. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2.
Bagaria SP; Ray PS; Sim MS; Ye X; Shamonki JM; Cui X; Giuliano AE
JAMA Surg; 2014 Feb; 149(2):125-9. PubMed ID: 24306257
[TBL] [Abstract][Full Text] [Related]
57. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
[TBL] [Abstract][Full Text] [Related]
58. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
59. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
60. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.
Fontein DBY; Klinten Grand M; Nortier JWR; Seynaeve C; Meershoek-Klein Kranenbarg E; Dirix LY; van de Velde CJH; Putter H
Ann Oncol; 2015 Jun; 26(6):1254-1262. PubMed ID: 25862439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
